Find your next paid study

Myosin Therapeutics Inc.NCT07185880

~$10 – $8,750

Phase 2

Enhanced Local Intensified Radiation Therapy in Elderly Glioblastoma (ELITE-GBM): A Phase 2 Hybrid Randomized Trial Leveraging External Data

Glioblastoma (GBM) is an aggressive malignancy of the central nervous system. Older adults with GBM have a unique constellation of medical, psychosocial, and s…

Glioblastoma (GBM)

Brigham and Women's HospitalNCT06835803

Phase 2

A Phase II, Multicenter, Prospective Study of Sacituzumab Govitecan in Recurrent Glioblastoma

This is an open-label single arm study. All patients will receive the study drug. The aim of the study is to compare overall survival (OS) of patients with rec…

Recurrent Glioblastoma

The University of Texas Health Science Center at San AntonioNCT04559230

Improving Understanding of Glioblastoma Through Preservation of Biologically Active Brain Tissue (PRESERVE GBM)

To collect and preserve glioblastoma tissue during standard of care tumor resection surgery and blood for future molecular and genetic testing. Tissue for rese…

GlioblastomaGlioblastoma MultiformeGliosarcoma

Baptist Health South FloridaNCT05756985

~$10 – $1,125

Glioblastoma MultiformeAnaplastic AstrocytomaGliosarcoma

A Phase I/II Study of Pembrolizumab and M032 (NSC 733972), a Genetically Engineered HSV-1 Expressing IL-12, in Patients With Recurrent/Progressive and Newly Diagnosed Glioblastoma Multiforme, Grade 3 or Grade 4 Astrocytoma, or Gliosarcoma

This Phase I (Cohort I and Cohort II) and Phase II trial is designed to confirm the safety and tolerability of Pembrolizumab when given in conjunction with M03…

University of Alabama at BirminghamNCT05084430

AstrocytomaGlioblastomaProgressive Disease

First-in Cancer-Type Phase I Study of FT536 for Recurrent WHO Grade 4 Astrocytoma

This is a single center, first-in cancer-type phase I clinical trial of FT536 for adult patients with recurrent WHO Grade 4 astrocytoma, irrespective of IDH-mu…

Masonic Cancer Center, University of MinnesotaNCT07560865

Central Nervous System NeoplasmsGlioblastomaGliosarcoma, Adult+20 more

A First-in-human Phase I Single-agent Dose-escalation, Food Effect and Dose Expansion Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms

The primary objective of this Phase 1, open-label, dose-escalation, and exploratory study is to evaluate the safety and tolerability profile (establish the max…

GlioblastomaHigh-grade GliomaGlioblastoma, IDH-wildtype+9 more

~$10 – $8,750

Jazz Pharmaceuticals

The SUPRAMAX-study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)

A greater extent of resection of the contrast-enhancing (CE) tumor part has been associated with improved outcomes in high-grade glioma patients. Recent result…

Jasper GerritsenNCT06118723

~$10 – $1,125

Phase 2

Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

To assess: * efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14 skipping mutations, NSCLC harboring MET amplification, solid …

Solid TumorsAdvanced CancerRenal Cancer+15 more

Apollomics Inc.NCT03175224

~$10 – $8,750

Magnetic Resonance Fingerprinting Guided Extended Resection in Glioblastomas

Magnetic resonance imaging, MRI, is a procedure that uses radio waves, a powerful magnet, and a computer to make a series of detailed pictures of areas inside …

GlioblastomaBrain Tumor

Case Comprehensive Cancer CenterNCT06455189

Recurrent GlioblastomaGlioblastomaGlioma, Malignant

Phase Ib Open-label Study of Adjuvant CUE-102, a WT-1-pHLA-IL2-Fc Fusion Protein in Glioblastoma (GBM) Patients at First Recurrence

The goal of this study is to evaluate the safety of the experimental drug, CUE-102, and establish the recommended dose of CUE-102 for participants with Recurre…

David Reardon, MDNCT06917885

~$10 – $7,500

Glioblastoma MultiformeAnaplastic AstrocytomaFibrillary Astrocytomas+5 more

Phase I/II Trial of Repeat Dosing of Super-Selective Intraarterial Infusion of Erbitux (Cetuximab) and Avastin (Bevacizumab) for Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age

This study assesses the safety and efficacy of repeat monthly dosing of super-selective intra-arterial cerebral infusion (SIACI) of cetuximab and bevacizumab i…